News
Real-world data supports tolvaptan use to slow kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback